Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

The disappointing results came on sales for Eylea, one of the company’s key products, dropping 26% to $1.04 billion amid pricing pressure and market share losses. Regeneron Pharmaceuticals ...

Unity’s restructuring comes along with 36-week results from its phase 2b Aspire trial that weighed its investigational eye treatment UBX1325 against Regeneron’s blockbuster Eylea in patients ...

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to ...

Wall Street’s trying to game the impact of Regeneron first big patent cliff as they lost protection for their EYLEA, that’s a blockbuster treatment for wet age-related macular degeneration.

Learn more about the diabetic macular edema treatment @ New Treatment for Diabetic Macular Edema EYLEA (Regeneron Pharmaceuticals) - Aflibercept is a recombinant fusion protein composed of the ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 5.25% to $598.76 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX ...

Regeneron Pharmaceuticals ... in our robust pipeline of differentiated clinical candidates. Beginning with EYLEA and EYLEA HD. On a macro basis, in the first quarter of 2025, the overall size ...

Regeneron's share of profits from the Sanofi collaboration rose to $1.02 billion. The company is navigating mixed regulatory outcomes. While the FDA accepted a priority review for EYLEA HD for ...

Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was rejected; this packaging format is important for the product's competitiveness with Vabysmo ...

Regeneron reported quarterly revenue contraction of 4% year on year, which was largely driven by declines in its Eylea franchise. Original dose Eylea declined 39% year on year and 38% sequentially ...